2025 ASCO GI 摘要标题公布！大会首日聚焦胃食管癌，超40项中国研究引领潮流

前言

2025年美国临床肿瘤学会胃肠道肿瘤研讨会（ASCO GI）将于1月23日至25日在加利福尼亚州旧金山举行，旨在为世界肿瘤学者传递国际消化肿瘤领域的最新研究进展。目前大会官网已披露了摘要标题，大会首日聚焦胃食管癌，超过40项中国研究入选，医脉通特此整理相关摘要标题，期待与广大读者一同抢先体验即将响起的中国强音。

Oral Abstract Session

01

摘要号：327

Intraperitoneal and intravenous paclitaxel plus S-1 versus intravenous paclitaxel plus S-1 in gastric cancer patients with peritoneal metastasis: Results from the multicenter, randomized, phase 3 DRAGON-01 trial

腹膜内和静脉注射紫杉醇联合S-1对比静脉注射紫杉醇联合S-1治疗腹膜转移胃癌患者：多中心、随机、III 期DRAGON-01试验的结果

讲者：严超 上海交通大学医学院附属瑞金医院

02

摘要号：LBA329

Preliminary results from the multicenter, randomized phase III trial (SCIENCE): Comparing chemotherapy plus sintilimab and chemoradiotherapy plus sintilimab versus chemoradiotherapy for neoadjuvant treatment in resectable locally advanced esophageal squamous cell carcinoma

多中心、随机 III 期试验（SCIENCE）的初步结果：对比化疗联合信迪利单抗、放化疗联合信迪利单抗与单独放化疗在可切除局部晚期食管鳞状细胞癌新辅助治疗中的疗效

讲者：冷雪峰 四川省肿瘤医院

Rapid Oral Abstract Session

01

摘要号：333

Efficacy and safety of albumin-bound docetaxel vs. docetaxel in patients with previously treated advanced gastric or gastroesophageal junction adenocarcinoma: A multicenter, randomized, phase II study.

白蛋白结合多西他赛对比多西他赛单药在既往接受过治疗的晚期胃或胃食管结合部腺癌患者中的疗效和安全性：一项多中心、随机、II 期研究

讲者：王志强 中山大学肿瘤防治中心

02

摘要号：334

Conversion effects of PD-1 inhibitor camrelizumab (Cam) combined with Nab-POF regimen in patients (pts) with initially unresectable locally advanced or limited metastatic gastric or gastroesophageal junction adenocarcinoma: FDZL-001 trial

PD-1抑制剂卡瑞利珠单抗（Cam）联合 Nab-POF 方案作为初始不可切局部晚期或局限性转移性胃或胃食管结合部腺癌患者的转化治疗：FDZL-001试验

讲者：耿其荣 复旦大学附属肿瘤医院

03

摘要号：335

Effect of SHR-1701 on chemotherapy (chemo)-induced myelosuppression: Data from a phase 3 study in HER2-negative gastric/gastroesophageal junction adenocarcinoma (G/GEJA)

SHR-1701对化疗（chemo）诱导的骨髓抑制的影响：来自HER2阴性胃/胃食管结合部腺癌（G/GEJA）的III 期研究数据

讲者：彭智 北京大学肿瘤医院

Poster session

01

摘要号：342

Real world data and biomarker analysis of the efficacy and safety of PD-1 inhibitor combined with chemotherapy in first-line treatment of advanced gastric cancer

讲者：Xiaoting Ma 中国医学科学院肿瘤医院

02

摘要号：343

Retreatment with immune checkpoint inhibitors (ICIs) for patients with advanced gastric cancer: A retrospective, real-world study

讲者：Yong-Xu Jia 郑州大学第一附属医院

03

摘要号：344

Nimotuzumab combined with chemotherapy plus immunotherapy as first-line treatment for advanced esophageal squamous cell carcinoma

讲者：Qi Wang 中国人民解放军总医院

04

摘要号：346

Prognostic analysis of pathological complete response after neoadjuvant therapy for locally advanced gastric cancer: A national, multicenter, retrospective study

讲者：Jie Chen 复旦大学附属肿瘤医院

05

摘要号：361

Preliminary results of the ALTER-E009 study: Efficacy and safety of anlotinib combined with radiotherapy in patients with locally advanced or metastatic esophageal squamous cell carcinoma (ESCC)—A multicenter, multi-cohort retrospective exploratory study

讲者：Xin Wang 中国医学科学院肿瘤医院

06

摘要号：367

Anlotinib combined with penpulimab and nab-paclitaxel as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): A single-arm, open-label phase II clinical trial

讲者：Zhiwei Chang 郑州大学第一附属医院

07

摘要号：368

Safety and efficacy of perioperative chemotherapy combined with PD-1 inhibitor versus chemotherapy with D2 gastrectomy plus PAND in gastric cancer with PALD metastasis: A single-center retrospective cohort study

讲者：Zeyao Ye 浙江省肿瘤医院

08

摘要号：375

Envafolimab in combination with lenvatinib and albumin paclitaxel for previously treated advanced GEJ adenocarcinoma: Latest analysis of a phase II, two-cohort study

讲者：XIAOYING ZHAO 复旦大学附属肿瘤医院

09

摘要号：390

An exploratory phase II trial of low-dose decitabine and sintilimab combined with chemotherapy in HER2-negative gastric or gastroesophageal junction adenocarcinoma

讲者：Yunyi Du 长治医学院附属长治人民医院

10

摘要号：392

First-line (1L) nivolumab (NIVO) plus chemotherapy (chemo) vs chemo in patients (pts) with advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma (GC/GEJC/EAC): 5-year (y) follow-up of Chinese pts from CheckMate 649

讲者：沈琳北京大学肿瘤医院

11

摘要号：395

Does chemotherapy regimen matter for first-line immunochemotherapy in low programmed cell death ligand 1 (PD-L1)-expressing esophageal squamous cell carcinoma (ESCC)? A systemic review and meta-analysis

讲者：Jhe-Cyuan Guo 台湾大学癌症中心

12

摘要号：396

Perioperative chemotherapy with either S-1 or 5-fluorouracil plus oxaliplatin and docetaxel for locally advanced gastric or gastroesophageal junction adenocarcinoma: A prospective trial and matched comparison

讲者：Chih Chieh Yen 台湾成功大学

13

摘要号：406

PD-1 inhibitor (sintilimab) and fruquintinib plus SOX as conversion therapy for initially unresectable gastric/gastroesophageal junction adenocarcinoma (GC/GEJC): Updated results from a single-arm, phase 2 clinical trial

讲者：Fei Ma 郑州大学附属肿瘤医院

14

摘要号：407

A phase II study of fruquintinib plus sintilimab as a second-line therapy for advanced gastric and gastroesophageal junction adenocarcinoma (GC/GEJC): Updated results

讲者：Min Jin华中科技大学同济医学院附属协和医院

15

摘要号：410

Neoadjuvant SHR-1701 (a bifunctional anti-PD-L1/TGF-βRII agent) combined with chemoradiotherapy for resectable locally advanced esophageal squamous cell carcinoma (ESCC): A phase II trial

讲者：Chengixn Liu 山东省肿瘤医院

16

摘要号：411

Bifunctional anti-PD-L1/TGF-βRII agent SHR-1701 plus chemotherapy as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): Survival results of a phase II trial

讲者：yi wang 山东大学齐鲁医院

17

摘要号：413

Response characteristics of tislelizumab (TIS) plus chemotherapy (chemo) in first-line (1L) treatment of locally advanced or metastatic esophageal squamous cell carcinoma (ESCC): A post hoc analysis of RATIONALE-306

讲者：Yi Li 中国人民解放军总医院

18

摘要号：414

Tislelizumab (TIS) + chemotherapy (chemo) vs placebo (PBO) + chemo as first-line (1L) treatment in gastric/gastroesophageal junction adenocarcinoma (GC/GEJC) patients with/without peritoneal or liver metastases: A post hoc analysis of RATIONALE-305 study

讲者：邱妙珍中山大学肿瘤防治中心

19

摘要号：421

Perioperative adebrelimab combined with chemotherapy for locally advanced resectable esophageal squamous cell carcinoma: A single-arm, open-label, multicenter study

讲者：Liang Dai 北京大学肿瘤医院

20

摘要号：423

Updated results from the phase Ib/II study of fruquintinib combined with SOX and toripalimab in patients with advanced metastatic gastric/gastroesophageal junction adenocarcinoma (GC/GEJC)

讲者：Xiangrui Meng 郑州大学第一附属医院

21

摘要号：424

An organ-preserving strategy in patients with esophageal squamous cell carcinoma treated with immunochemotherapy

讲者：Bo Zhang中国医学科学院肿瘤医院

22

摘要号：436

Transarterial infusion chemotherapy and embolization (TAICE) as a pre-operative therapy for patients with locally advanced gastric cancer (LAGC): A prospective, single-arm, pilot study

讲者：Zheng Liu 复旦大学附属中山医院

23

摘要号：437

Chemoimmunotherapy plus radiotherapy in advanced esophageal squamous-cell carcinoma

讲者：Keke Nie 青岛市中心医院

24

摘要号：440

HLX22 plus trastuzumab and XELOX for first-line treatment of HER2-positive locally advanced or metastatic gastric/gastroesophageal junction cancer (G/GEJC): Updated results with additional patients

讲者：李进中国药科大学附属上海高博肿瘤医院

25

摘要号：442

Paclitaxel oral solution versus paclitaxel injection as a second-line therapy in advanced gastric cancer: A randomized, open-label, non-inferiority phase 3 trial

讲者：李进中国药科大学附属上海高博肿瘤医院

26

摘要号：443

Neoadjuvant adebrelimab plus chemotherapy for resectable locally advanced esophageal squamous cell carcinoma: A phase 2 trial

讲者：Zhigang Li 上海交通大学医学院附属胸科医院

27

摘要号：444

Preliminary results of benmelstobart plus anlotinib combined with SOX in the first-line treatment of advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma with low PD-L1 expression: A single-arm, multicenter phase II clinical trial

讲者：Yong-Xu Jia 郑州大学第一附属医院

28

摘要号：445

Fruquintinib plus camrelizumab combined with paclitaxel liposome and nedaplatin as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): A single-arm, phase II clinical trial

讲者：Yanhong Gu 江苏省人民医院

29

摘要号：450

Tislelizumab (Tisle) combined with POFI (irinotecan, paclitaxel, oxaliplatin and 5-FU/levoleucovorin) as first-line treatment of advanced gastric/gastroesophageal junction adenocarcinoma (AGC): OS analysis results of the SYLT-023

讲者：Liyu Su 福建医科大学肿瘤医院

30

摘要号：454

Updated efficacy results of ASKB589 combined with CAPOX and PD-1 inhibitor as first-line treatment for metastatic gastric/gastro-esophageal junction (G/GEJ) adenocarcinoma from a phase Ib/II study

讲者：彭智北京大学肿瘤医院

31

摘要号：459

Anlotinib plus benmelstobart as adjuvant therapy in patients with esophageal squamous cell carcinoma: A phase II clinical trial (ALTER-E005)

讲者：Changying Guo 江西省肿瘤医院

32

摘要号：460

Clinical study of radiotherapy combined with tegafur bolus synchronization in the treatment of inoperable elderly middle and advanced esophageal cancer

讲者：Xixi Zhao 西安交通大学第二附属医院

33

摘要号：461

Fruquintinib combined with PD-1 inhibitors and chemotherapy in the first-line treatment of HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma (FDZL-FIX): A single-arm, open-label phase 2 study

讲者：Chenchen Wang 复旦大学附属肿瘤医院

34

摘要号：463

Efficacy, safety and DNA methylation analysis of cadonilimab combined with taxane and cisplatin as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): Updated results from an open-label, multicenter phase II trial (AK104-IIT-014)

讲者：Wang Qu中国医学科学院肿瘤医院

35

摘要号：464

Pembrolizumab or placebo plus chemotherapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: An updated analysis of KEYNOTE-859 for patients enrolled in Asia

讲者：CHIA JUI YEN 台湾成功大学

36

摘要号：472

Unraveling the role of interferon-stimulated neutrophils: A promising biomarker for immunotherapy efficacy and prognosis in gastric adenocarcinoma

讲者：Hongda Pan 复旦大学附属肿瘤医院

37

摘要号：475

Effect of tRF-28-ZJ47D112Z4DZ on the pathogenesis of gastric cancer through targeting cyclin D1/CDK4 and its early diagnostic value

讲者：Yu Xiuchong 宁波大学附属第一医院

38

摘要号：483

Use of nucleotyping and tumor stroma ratio to predict prognosis in patients with resected intestinal-type gastric cancer

讲者：Dan Sha 山东第一医科大学附属省立医院

39

摘要号：484

Histopathological growth patterns of gastric cancer liver metastasis and their association with patient prognosis

讲者：Dan Sha 山东第一医科大学附属省立医院

40

摘要号：488

‍‍‍‍‍‍‍‍‍‍‍Use of immune repertoire sequencing analysis to detect differences in treatment responses for advanced esophageal squamous cell carcinoma treated with camrelizumab and platinum-based chemotherapy

讲者：Jun Zhao 长治医学院附属长治人民医院

Trials in Progress Poster Session

01

摘要号：TPS506

Neoadjuvant cadonilimab plus anlotinib followed by surgery for locally advanced esophageal squamous cell carcinoma: A single arm, phase 2 trial

讲者：Wenhan Weng 北京大学人民医院

备注：排名不分先后，按照摘要号进行排序

如有遗漏或任何问题，请给我们留言~

撰写：Aurora

排版：Aurora

执行：Squid

医脉通是专业的在线医生平台，“感知世界医学脉搏，助力中国临床决策”是平台的使命。医脉通旗下拥有「临床指南」「用药参考」「医学文献王」「医知源」「e研通」「e脉播」等系列产品，全面满足医学工作者临床决策、获取新知及提升科研效率等方面的需求。

本平台旨在为医疗卫生专业人士传递更多医学信息。本平台发布的内容，不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议。如该等信息被用于了解医学信息以外的目的，本平台不承担相关责任。本平台对发布的内容，并不代表同意其描述和观点。若涉及版权问题，烦请权利人与我们联系，我们将尽快处理。